查詢結果分析
相關文獻
- 利用全國藥物不良反應通報資料探討新型口服抗凝血藥品之出血相關風險
- 新型口服抗凝血劑--心房顫動中風預防的新曙光
- “耳”目一新的心房顫動預防中風新治療:左心耳封堵術
- 醫療人員對藥品不良反應通報應有的認知及態度
- 藥品不良反應監視及通報系統
- Sudden Cardiac Death Following Verapamil in a Patient with Wolff-Parkinson-White Syndrome and Dilated Cardiomyopathy--A Case Report and Literature Review Based on Emergency Viewpoints
- 心房顫動的最新治療
- Late Development of Persistent Atrial Fibrillation with Loss of AAI Mode Pacemaker Function and Superior Vena Cava Syndrome--Report of a Case of Sick Sinus Syndrome with Such Complications and Review of Literature
- Electrical Remodeling in Atrial Fibrillation
- 藥品不良反應通報作業簡介
頁籤選單縮合
題 名 | 利用全國藥物不良反應通報資料探討新型口服抗凝血藥品之出血相關風險=Investigation of Novel Oral Anticoagulants-related Hemorrhagic Risks Using National Adverse Drug Reaction Reporting System in Taiwan |
---|---|
作 者 | 謝松佑; 陳彥瑋; 陳家蓁; 柯韋名; 黃薇伊; 蕭斐元; | 書刊名 | 臺灣醫學 |
卷 期 | 20:1 2016.01[民105.01] |
頁 次 | 頁16-24 |
分類號 | 418.2321 |
關鍵詞 | 新型口服抗凝血藥品; 胃腸道出血; 心房顫動; 中風預防; 藥品不良反應; Rivaroxaban; Dabigatran; Novel oral anticoagulants; NOACs; Gastrointestinal bleeding; Atrial fibrillation; Stroke prevention; Adverse drug reaction; |
語 文 | 中文(Chinese) |
中文摘要 | 新型口服抗凝血藥品(novel oral anticoagulants,NOACs)如rivaroxaban或dabigatran經臨床試驗證 實具有如warfarin能有效地預防心房纖維顫動病人發生中風的療效。然而,目前研究指出NOACs相較於warfarin有較高的腾胃道出血風險。本研究之目的為分析台灣不良反應通報案例中與rivaroxaban與dabigatran相關之出血風險,並進一步分析案例是否併有可能增加出血的危險因子。結果顯示使用NOACs最常見的出血部位為腸胃道出血,且許多個案本身併有可能增加出血的危險因子,如高齡、腎功能不全者或併用容易出血的藥品。因此本研究建議醫療照護人員於臨床使用NOACs時,對本身已具有會增加出 血危險因子的病人應定期監測腎功能並謹慎地做劑量調整,以減少藥品相關之出血不良反應。 |
英文摘要 | In clinical trials, novel oral anticoagulants (NOACs) have proven to be as effective as warfarin for stroke prevention in patients with atrial fibrillation. However, most meta-analyses of phase III randomized controlled trials and observational studies have shown a higher incidence of gastrointestinal bleeding among NOACs than warfarin users in patients with atrial fibrillation. Using reporting cases from Taiwan's National Adverse Drug Reaction Reporting System, the objective of this study was to examine hemorrhagic events associated with associated with two NOACs: rivaroxaban and dabigatran. Risk factors for hemorrhagic events among these cases were further explored. We found gastrointestinal hemorrhage was the most frequently reported bleeding site associated with rivaroxaban and dabigatran uses. In addition, our study identified several risk factors associated with NOACs-related hemorrhagic events, such as older age, impaired renal function or concomitant use of drugs with potential bleeding risk. Therefore, close monitoring of renal function and dosage adjustment for those with risk factors are suggested to reduce NOACs-associated hemorrhagic events. |
本系統中英文摘要資訊取自各篇刊載內容。